

**Amendments to the Claims**

Please amend the application by canceling all of the claims now present without prejudice and entering the new claims as set forth in the below List of Claims.

**List of Claims**

- 1-40. Cancelled.
41. (New) A substantially pure polynucleotide comprising a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO:2, wherein said protein promotes multidrug resistance when expressed in a host cell.
42. (New) The substantially pure polynucleotide of claim 41, wherein said polynucleotide consists essentially of a nucleotide sequence encoding a protein with the amino acid sequence of SEQ ID NO:2.
43. (New) The substantially pure polynucleotide of claim 41, wherein said polynucleotide consists of a nucleotide sequence encoding a protein with the amino acid sequence of SEQ ID NO:2.
44. (New) A substantially pure polynucleotide comprising the nucleotide sequence of SEQ ID NO:10.
45. (New) A substantially pure polynucleotide consisting essentially of the nucleotide sequence of SEQ ID NO:10.
46. A substantially pure polynucleotide consisting of the nucleotide sequence of SEQ ID NO:10.
47. (New) An expression vector comprising the polynucleotide of any one of claims 41-46.
- See Examiner's  
A  
B  
C*

*6-26-04*  
*substantially pure*

48. (New) A host cell that has been transformed with the expression vector of claim 47.
49. (New) The host cell of claim 48, wherein said host cell is selected from the group consisting of: NIH-3T3 cells; CHO cells; HeLA cells; and LM(tk-) cells. ✓